IDARUBICINA ACCORD 5mg / 5ml injectible solution medication leaflet

L01DB06 idarubicin • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances

Idarubicin is a chemotherapy drug used for the treatment of acute leukemia, including acute myeloid leukemia (AML). It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, thereby preventing cell division.

The medication is administered intravenously, as directed by a doctor. It is important to monitor the patient for adverse effects during treatment.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, or cardiac toxicity. In rare cases, severe allergic reactions may occur.

Idarubicin is not recommended for patients with severe cardiac insufficiency, severe bone marrow suppression, or hypersensitivity to anthracyclines.

General data about IDARUBICINA ACCORD 5mg / 5ml

Substance: idarubicin

Date of last drug list: 01-03-2022

Commercial code: W63523001

Concentration: 5mg / 5ml

Pharmaceutical form: injectible solution

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE

Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA

Number: 9744/2017/01

Shelf life: 2 years;after the first opening-it is used immediately

Pharmaceutical forms available for idarubicin

Concentrations available for idarubicin

10mg, 10mg/10ml, 20mg/20ml, 5mg, 5mg/5ml

Other substances similar to idarubicin